A Quick Overview of Diffuse Large B-Cell Lymphoma (DLBCL) at ASCO 2022
Diffuse Large B Cell Lymphoma is a deadly blood cancer that is the most frequent kind of non-Hodgkin lymphoma (NHL), with over 40,000 new cases diagnosed in Europe each year and another 25,000 in the United States.
While the ASCO 2022 annual meeting is approaching, pharma behemoths such as Seagen, Hoffmann-La Roche, and others are seeking the opportunity to share research on several cancers, including Diffuse Large B Cell Lymphoma. Delveinsight has collated all of the future key abstracts while addressing a handful of them, all while preserving a sense of brevity.
Abstract Number – 7500
Roche will discuss glofitamab's pivotal Phase II expansion data in patients with R/R DLBCL Cancer. Will there be a follow-up to Polivy's first-in-class CD20xCD3 T-cell engaging bispecific antibody?
Glofitamab is part of Roche's larger bispecific antibody development program, which could lead to a new immunotherapy-based treatment option for a variety of blood malignancies. According to recent data, 51.6 percent of patients responded to glofitamab treatment, with 39.4 percent of these patients achieving a complete response, the bulk of which (almost 78 percent) persisting for at least 12 months.
Apart from that, the findings suggest that glofitamab could be a good partner for Roche's CD79b-directed ADC Polivy (Polatuzumab Vedotin), which was approved in the EU earlier this week for previously untreated DLBCL and is expected to be a USD 2 billion blockbuster. Based on these findings, glofitamab appears to have the potential to provide a therapeutic benefit.
According to the above-mentioned positive outcomes, the upcoming pivotal results are expected to be encouraging, bolstering the promise of glofitamab for patients who have failed several prior lines of therapy and urgently require new therapeutic alternatives. We eagerly await the results of the Phase II trial, which will be presented as an oral abstract session at the ASCO Conference 2022, on June 3, 2022.
Abstract Number - 7559
Seagen’s Adcetris (Brentuximab Vedotin), an antibody-drug conjugate for R/R DLBCL
Seagen is about to present the Phase III ECHELON-3 study's safety and effectiveness findings. ADCs are a promising class of immunotherapies that have the ability to target tumour cells specifically while also improving the therapeutic index of cytotoxic medicines. Because ADC efficacy and safety have progressed in lockstep with developments in their design, the findings from the ECHELON-3 research will be presented as a poster session at the ASCO Meeting 2022 on June 4, 2022.
Conclusion
Glofitamab is one step closer to discovering a cure for people with heavily pre-treated diffuse large B-cell lymphoma, which frequently relapses and becomes more aggressive, thanks to new evidence. Furthermore, glofitamab's promise as a new fixed-duration, readily available medication could be critical in improving outcomes for those with this difficult-to-treat cancer who have few other options. The most sought data for this cancer is the expansion results from the upcoming Phase II trial in DLBCL. Apart from that, ADCs will play a critical role in the treatment of patients with R/R DLBCL. As a result, it will be fascinating to follow the outcomes of these two distinct classes of therapy.
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage
Some of the Latest ASCO Abstract 2022 Launched:
- Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)?
- Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022.
- Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer
Trending & Popular Healthcare Market Research Reports Given By DelveInsight
Parainfluenza Virus Infection Market
Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the Parainfluenza Virus Infection forecasted epidemiology.
Paranasal Sinus Cancer Market Insights, Epidemiology, Market Forecast report delivers an in-depth understanding of the Paranasal Sinus Cancer epidemiology
Transient Ischemic Attack Market
DelveInsight's Transient Ischemic Attack Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Transient Ischemic Attack forecasted epidemiology
CAR-T Pipeline Insights, 2022 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the CAR-T market
Plaque Modification Devices Market
DelveInsight’s ‘Plaque Modification Devices -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Plaque Modification Devices
DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology
DelveInsight's Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology
DelveInsight's SGLT2 inhibitors Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the SGLT2 inhibitors, historical and forecasted epidemiology
Varicose Vein Treatment Devices Market
DelveInsight’s ‘Varicose Vein Treatment Devices -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Varicose Vein Treatment
Brucellosis Market Insights, Market Forecast report delivers an in-depth understanding of the Brucellosis, historical and forecasted epidemiology, and the Brucellosis market trends in 7MM.
DelveInsight’s ‘Orthopedic Splints -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Orthopedic Splints..
Inflammatory Pain Market Insights, Epidemiology, and Market Forecast-2032 report deliver an understanding of the forecasted epidemiology, and the Inflammatory Pain market trends in 7MM.
DelveInsight's Testicular Neoplasm Market Insights, Epidemiology, and Market Forecast report delivers an understanding of forecasted epidemiology and the Testicular Neoplasm market trends in 7MM
Latest Healthcare Research Reports 2022 By DelveInsight
B Cell Chronic Lymphocytic Leukemia Market
Opioid-related Disorders Market
Polycystic Kidney Disease Market
Coronary Microvascular Dysfunction CMD Market
Oncolytic Virus Cancer Therapy Pipeline
Comments
Post a Comment